This Medical Letter review summarizes the use of tixagevimab and cilgavimab (Evusheld), investigational long-acting monoclonal antibodies to be administered concomitantly by intramuscular injection for preexposure prophylaxis of COVID-19 in persons aged 12 years or older.
Tixagevimab and Cilgavimab (Evusheld) for Pre-Exposure Prophylaxis of COVID-19: The Journal of the American Medical Association